MeSH D011125 - adenomatous polyposis coli
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D015179:Colorectal neoplasms
D044483:Intestinal polyposis
0 Companies
0 Drugs
Success rate
D018256:Adenomatous polyps
0 Companies
0 Drugs
Success rate
D009386:Hereditary neoplastic syndromes
0 Companies
0 Drugs
Success rate
D011125:Â
Adenomatous polyposis coli
D005736:Gardner syndrome
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Celecoxib | Celecoxib |  | 2014-05-30 |  |  |
| Mylan | Celecoxib | Celecoxib |  | 2014-05-30 |  |  |
| Cipla | Celecoxib | Celecoxib |  | 2015-09-23 |  |  |
| Lupin Research | Celecoxib | Celecoxib |  | 2014-10-29 |  |  |
| Pfizer | Celecoxib | Onsenal |  | 2003-10-17 |  |  |
| Aurobindo Pharma | Celecoxib | Celecoxib |  | 2016-02-01 |  |  |
| Alembic Pharmaceuticals | Celecoxib | Celecoxib |  | 2015-08-21 |  |  |
| Apotex | Celecoxib | Celecoxib |  | 2015-06-02 |  |  |
| CSPC Ouyi Pharmaceutical | Celecoxib | Celecoxib |  | 2018-01-23 |  |  |
| Macleods Pharma | Celecoxib | Celecoxib |  | 2016-03-16 |  |  |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
0%0/2
Phase 2
42%5/12
Phase 3
33%3/9
Approved: 2Overall Success rate: 0%
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use